Argatroban anticoagulation in patients with heparin-induced thrombocytopenia

Cardiovascular Reviews and Reports

Volumn 23, Issue 8, 2002, Pages 445-454+457

  Lewis, Bruce E ^a   Walenga, Jeanine M ^a   Hursting, Marcie J ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; HEPARIN;

ANTICOAGULATION; CROSS REACTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; IMMUNE MEDIATED INJURY; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0036329827     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Heparin-associated thrombocytopenia
2. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY216)
3. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaron (Org 10172)
4. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight-heparin or unfractionated heparin
5. A 14-year study of heparin-induced thrombocytopenia
6. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia
7. Heparin-induced thrombocytopenia: A clinico-pathologic syndrome
8. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
9. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
10. Temporal aspects of heparin-induced thrombocytopenia
11. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
12. Heparin-induced thrombocytopenia: Pathogenesis, management, and prevention
13. Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome
14. Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia, Blood Coagul Fibrinolysis
15. The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome
16. Argatroban re-exposure in patients with heparin-induced thrombocytopenia
17. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia
18. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia
19. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT and clinical relevance
20. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
21. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction
22. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects
23. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin
24. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin
25. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents
26. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia
27. Potent inhibition of thrombin by the newly synthesized arginine derivative no 805. The importance of stereostructure of its hydrophobic carboxamide portion
28. 2-[(3-methyl-1,2,3,4- tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2-piperidinecarboxylic acid
29. Crystallographic analysis at 3.0-Å resolution of the binding to human thrombin of four active site-directed inhibitors
30. Synthetic selective inhibitors of thrombin
31. Pharmacokinetic studies of argatroban (MD-805): Protein binding and blood cell binding
32. Pharmacokinetic studies of argatroban (MD-805) in human: Concentrations of argatroban and its metabolites in plasma, urine and feces during and after drip intravenous infusion
33. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban
34. Phase one study of synthetic antithrombin agent (MD-805) single and multiple administration studies
35. Combined administration of aspirin and a specific thrombin inhibitor in man
36. Coagulation laboratory testing patients treated with argatroban
37. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin
38. Investigation of interaction between argatroban and acetaminophen, lidocaine, or digoxin
39. The International Normalized Ratio during concurrent warfarin and argatroban anticoagulation: Differential contributions of each agent and effects of the choice of thromboplastin used
40. Effect of synthetic thrombin inhibitor (MD-805) as an alternative drug on heparin-induced thrombocytopenia during hemodialysis
41. Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis
42. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial infarction with Novastan and TPA (MINT) study
43. Argatroban and alteplase in patients with acute myocardial infarction: The ARGAMI study
44. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris
45. Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: A multicenter clinical trial of argatroban
46. Argatroban during percutaneous transluminal coronary angioplasty: Results of a dose-verification study
47. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis
48. Thrombin inhibitors in unstable angina: Rebound or continuation of angina after argatroban withdrawal?